3Kato Y, Kudo M, Shinkawa T, et al. Role of O-linked carbohy- drate of human urinary trypsin inhibitor on its lysosomal membrane- stabilizing property [ J]. Biochem Biophys Res Commun, 1998, 243 (2) : 377-383.
4Uemura K, Murakami Y, Hayashidani Y, et al. Randomized clini- cal trial to assess the efficacy of ulinastatin for postoperative pancre- atitis following pancreaticoduodenectomy[ J]. J Surg Oncol, 2008, 98(5) :309-313.
5Huang N, Wang F, Wang Y, et al. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis[J]. J Surg Res, 2013,182(2) :296-302.
6Tanaka R, Fujita M, Tsuruta R, et al. Urinary trypsin inhibitor suppresses excessive generation of superoxidc anion radical, systemic inflammation, oxidative stress, and endothelial injury in endotoxemic rats[ J]. Inflamm Res, 2010,59 (8) :597-606.
7Xu CE, Zhang MY, Zou CW, et al. Evaluation of the pharmaco- logical function of ulinastatiu in experimental animals [ J ]. Mole- cules, 2012,17 ( 8 ) :9070-9080.
8Jeong CW, Lee CS, Lee SH, et al. Urinary trypsin inhibitor attenuates liver enzyme elevation after liver resection [ J ]. Korean J Anesthesiol, 2012,63 ( 2 ) : 120-123.
9Ueki M, Tale S, Chujo K, et al. Urinary trypsin inhibitor re- duces inflammatory response in kidney induced by lipopolysac- charide[J]. JBiosciBioeng, 2007,104(4):315-320.
10Kim SJ, Yoo KY, Jeong CW, et al. Urinary trypsin inhibitors afford cardioprotective effects through activation of PI3K-Akt and ERK signal transduetion and inhibition of p38 MAPK and JNK[J]. Cardiology, 2009,114(4) :264-270.
